Accounting for Cured Patients in Cost-Effectiveness Analysis

• Published in: Value in health Vol. 20; no. 4; pp. 705 - 709
• Main Authors: Othus, Megan, Bansal, Aasthaa, Koepl, Lisel, Wagner, Samuel, Ramsey, Scott
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2017; Elsevier Science Ltd
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - economics; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - adverse effects; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Bias; Cancer; Clinical research; Clinical trials; Confidence intervals; Cost analysis; Cost-Benefit Analysis; Cure; cure models; Data processing; Drug Costs; Economics; Female; Glycoprotein gp100; Glycoproteins - adverse effects; Glycoproteins - economics; Glycoproteins - therapeutic use; Health economics; Heterogeneity; Humans; Internal Medicine; Ipilimumab; Kaplan-Meier Estimate; Male; Medical treatment; Melanoma; Melanoma - drug therapy; Melanoma - economics; Melanoma - mortality; Middle Aged; Models, Economic; Monoclonal antibodies; Mortality; Oncology; overall survival; Quality adjusted life years; Randomized Controlled Trials as Topic; Remission Induction; Skin melanoma; Skin Neoplasms - drug therapy; Skin Neoplasms - economics; Skin Neoplasms - mortality; Statistical analysis; Statistical methods; Survival analysis; Survivor; Survivors; Time Factors; Treatment Outcome; Young Adult; overall survival; cure models; survival analysis; oncology

Economic evaluations often measure an intervention effect with mean overall survival (OS). Emerging types of cancer treatments offer the possibility of being “cured” in that patients can become long-term survivors whose risk of death is the same as that of a disease-free person. Describing cured and...